
|Articles|February 15, 2002
- BioPharm International-02-01-2002
- Volume 15
- Issue 2
Sale of Your Product Can Prevent Patenting: How to Avoid the On-Sale Bar
Author(s)Tom Brody
By Tom Brody, DNAX Research Institute, pp. 38-42. Early sale or offers to sell an invention may result in the rejection of a patent application under 35 U.S.C. 102(b). Such a rejection is called "the on-sale bar," and it permanently prevents patenting of an invention.
Advertisement
Articles in this issue
over 23 years ago
Outsourcing Outlook: Reaping the Benefits of E-Procurementover 23 years ago
The Immunogenicity of Therapeutic Proteinsover 23 years ago
Inside Washington: Costs and Controls Challenge Manufacturersover 23 years ago
21 CFR Part 11: (Un)Expected Added ValueNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
Why Flexibility and Commercial Viability Must Be Built-in Early for Scaling CGTs
2
How Rentschler Biopharma’s New Platforms Aim to Accelerate Biologics Development in Asia
3
Analyzing the Safety and Scope of Next-Generation Gene Editing Platforms
4
Selecting the Right Drug Delivery Formulations to Enhance Patient-Centric Care
5